Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: A report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 388-400

  Dubbink, Hendrikus J ^a   Atmodimedjo, Peggy N ^a   Kros, Johan M ^a   French, Pim J ^b   Sanson, Marc ^c   Idbaih, Ahmed ^d   Wesseling, Pieter ^e   Enting, Roelien ^f   Spliet, Wim ^g   Tijssen, Cees ^h   Dinjens, Winand N M ^a   Gorlia, Thierry ⁱ   Van Den Bent, Martin J ^j  

^a Department of Pathology ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

ⁱ EORTC DATA CENTER   (Belgium)

^j ERASMUS MC CANCER INSTITUTE   (Netherlands)

more..

Author keywords

1p 19q; methylation; next generation sequencing; oligodendroglioma; PCV

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NOTCH RECEPTOR; PROCARBAZINE; TELOMERASE REVERSE TRANSCRIPTASE; VINCRISTINE; ISOCITRATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; ATRX GENE; BRAF GENE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHROMOSOME 1Q; CHROMOSOME 9Q; CIC GENE; COPY NUMBER VARIATION; DNA METHYLATION; EGFR GENE; FUBP1 GENE; GENE; GENE MUTATION; H3F3A GENE; HISTOPATHOLOGY; HUMAN; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; NOTCH GENE; OLIGODENDROGLIOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PI3KC GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PTEN GENE; TERT GENE; TUMOR SUPPRESSOR GENE; ADJUVANT CHEMOTHERAPY; AGED; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETICS; GLIOMA; HIGH THROUGHPUT SEQUENCING; MALE; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GLIOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; OLIGODENDROGLIOMA; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES;

EID: 84960077443     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov182     Document Type: Article

References (49)

1. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol. 2010;120(3):297-304.
2. Burger PC. What is an oligodendroglioma? Brain Pathol. 2002; 12(2):257-259.
3. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from EORTC trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neuropathol Exp Neurol. 2007;66(6):545-551.
4. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase iii trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-5880.
5. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol. 2009; 11(6):737-746
6. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q Deletion and clinical outcome in intergroup radiation therapy oncology group trial 9402. Brain Pathol. 2008;18(3):360-369.
7. Miller CR, DunhamCP, Scheithauer BW, et al. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol. 2006;24(34):5419-5426.
8. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
9. Hegi ME, Janzer RC, Lambiv WL, et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol. 2012;123(6):841-852.
10. Figarella-Branger D, Mokhtari K, Colin C, et al. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathol. 2015;25(4):418-428.
11. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56(10):1098-1104.
12. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014; 128(4):551-559.
13. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
14. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013;31(3): 344-350.
15. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Canc Inst. 1998;90(19): 1473-1479.
16. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18(3):636-645.
17. Labussiere M, Di Stefano AL, Gleize V, et al. TERTpromotermutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 2014;111(10):2024-2032.
18. Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014;5(6):1515-1525.
19. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-1604.
20. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-722.
21. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133-146.
22. Killela PJ, Reitman ZJ, Jiao Y,, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6026.
23. Grasso C, Butler T, Rhodes K, et al. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn. 2015;17(1):53-63.
24. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011; 333(6048):1453-1455.
25. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7-16.
26. van den Bent MJ, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol. 2013; 112(2):173-178.
27. van Lier MG, Wagner A, van Leerdam ME, et al. A review on the molecular diagnostics of Lynch syndrome: A central role for the pathology laboratory. J Cell Mol Med. 2010;14(1-2):181-197.
28. Idbaih A, Dalmasso C, Kouwenhoven M, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol. 2011;103(2):221-230.
29. van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013;19(19): 5513-5522.
30. Geurts-Giele WR, Leenen CH, Dubbink HJ, et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J Pathol. 2014;234(4):548-559.
31. Giardine B, Riemer C, Hardison RC, et al. Galaxy: A platform for interactive large-scale genome analysis. Genome Res. 2005; 15(10):1451-1455.
32. Goecks J, Nekrutenko A, Taylor J. Galaxy: A comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 2010;11(8):R86.
33. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
34. Koopmans AE, Ober K, Dubbink HJ, et al. Prevalence and implications of TERTpromoter mutation in uveal and conjunctivalmelanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2014;55(9):6024-6030.
35. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547-560.
36. Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics. 2000;56(1):249-255.
37. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-387.
38. Heinze G, Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed. 2003;71(2):155-163.
39. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. Journ of Comp Graph Stat. 2006;15(2):651-674.
40. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-231.
41. Figarella-Branger D, Mokhtari K, Dehais C, et al. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol. 2014;16(9): 1244-1254.
42. Reyes-Botero G, Dehais C, Idbaih A, et al. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol. 2014;16(5):662-670.
43. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443-451.
44. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012;124(5): 615-625.
45. Wang XW, Ciccarino P, Rossetto M, et al. IDH mutations: genotype-phenotype correlation and prognostic impact. Biomed Res Int. 2014;2014:540236.
46. Cairncross JG,Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783-790.
47. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498.
48. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508.
49. Louis DN, Perry A, Burger P, et al. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014; 24(5):429-435.